Vertex says about 20 patients have started sickle cell therapy; cuts two rare disease programs

Vertex Pharmaceuticals is picking up momentum in its strategy of branching out beyond cystic fibrosis.

About 20 patients have had their cells collected for Casgevy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sanofi and Regeneron’s blockbuster Dupixent rejected by FDA for chronic hives condition

US regulators want to see more efficacy data before they consider approving Sanofi and Regeneron’s Dupixent in a skin condition characterized by chronic hives, Sanofi

October 24, 2023

Greenlane Announces Board’s Approval of Reverse Stock Split Ratio

BOCA RATON, FL / ACCESSWIRE / June 2, 2023 / Greenlane Holdings, Inc. (NASDAQ:GNLN) (“Greenlane”), one of the largest global sellers of premium cannabis accessories,

June 3, 2023

Rise in human life expectancy may be slowing down

Research indicates that without major advances in aging, radical life extension is improbable, necessitating reforms in retirement planning and life insurance.

October 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.